scholarly journals Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Diabetologia ◽  
2011 ◽  
Vol 54 (12) ◽  
pp. 3093-3100 ◽  
Author(s):  
S. L. Samson ◽  
P. Sathyanarayana ◽  
M. Jogi ◽  
E. V. Gonzalez ◽  
A. Gutierrez ◽  
...  
Keyword(s):  
Liver Disease ◽  
Growth Factor ◽  
Randomised Controlled Trial ◽  
Fatty Liver Disease ◽  
Controlled Trial ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Alcoholic Fatty Liver ◽  
Randomised Controlled ◽  
Alcoholic Fatty Liver Disease

Fibroblast growth factor 21 in non-alcoholic fatty liver disease

Metabolism ◽  
2019 ◽  
Vol 101 ◽  
pp. 153994 ◽  
Author(s):  
Bradley Tucker ◽  
Huating Li ◽  
Xiaoxue Long ◽  
Kerry-Anne Rye ◽  
Kwok Leung Ong
Keyword(s):  
Liver Disease ◽  
Growth Factor ◽  
Fatty Liver ◽  
Fibroblast Growth Factor ◽  
Fatty Liver Disease ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document